Results 271 to 280 of about 150,085 (313)
Young People With Type 2 Diabetes Are Under‐Represented in Randomized Clinical Trials
Diabetes, Obesity and Metabolism, EarlyView.
Bowei Yu +3 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Vascular Medicine, 2004
Clinical studies have shown that hydroxy-methyl glutaryl coenzyme A reductase inhibitors (statins) may favorably affect atherothrombosis. In addition to their potent cholesterol-lowering properties, statins reduce atheroma progression as well as the incidence of acute thrombosis-related vascular events and their dreadful clinical consequences ...
S. Colli, J. P. Werba, E. Tremoli
openaire +2 more sources
Clinical studies have shown that hydroxy-methyl glutaryl coenzyme A reductase inhibitors (statins) may favorably affect atherothrombosis. In addition to their potent cholesterol-lowering properties, statins reduce atheroma progression as well as the incidence of acute thrombosis-related vascular events and their dreadful clinical consequences ...
S. Colli, J. P. Werba, E. Tremoli
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America, 2015
Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety.
Cynthia, Herrick +2 more
openaire +3 more sources
Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety.
Cynthia, Herrick +2 more
openaire +3 more sources
Cardiology Clinics, 2015
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes.
Kevin C, Maki +2 more
openaire +3 more sources
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes.
Kevin C, Maki +2 more
openaire +3 more sources
Current Medicinal Chemistry, 2008
Pharmacological studies highlighted pleiotropic effects of statins, that seem to influence atherogenesis not only by increasing atherosclerotic plaque stability but also by modulating endothelial function and inflammation and acting on platelet aggregation and thrombosis.
Bersano A +5 more
openaire +3 more sources
Pharmacological studies highlighted pleiotropic effects of statins, that seem to influence atherogenesis not only by increasing atherosclerotic plaque stability but also by modulating endothelial function and inflammation and acting on platelet aggregation and thrombosis.
Bersano A +5 more
openaire +3 more sources
All for Statins and Statins for All; An Update
Current Pharmaceutical Design, 2015Statins exert beneficial effects on cardiovascular [CV] outcomes as well as on inflammation and oxidative stress. The widespread use of statins for both primary and secondary CV disease prevention is based on the evidence from large randomized controlled trials. The benefits of statin treatment outweigh any harm in high risk patients. In this narrative
Aris P, Agouridis +3 more
openaire +2 more sources
The Lancet, 1999
Sir—Robert Rosenson and colleagues (March 20, p 983) investigate whether pravastatin modifies the production o f proinflammatory cytokines that regulate vascular tone, plaque stability, and thrombogenesis. They measured concentrations of peripheral blood samples after 6 h of incubation with lipopolysaccharide (LPS) and showed that LPS-stimulated ...
U, Ikeda, K, Shimada
openaire +2 more sources
Sir—Robert Rosenson and colleagues (March 20, p 983) investigate whether pravastatin modifies the production o f proinflammatory cytokines that regulate vascular tone, plaque stability, and thrombogenesis. They measured concentrations of peripheral blood samples after 6 h of incubation with lipopolysaccharide (LPS) and showed that LPS-stimulated ...
U, Ikeda, K, Shimada
openaire +2 more sources
BMJ, 2014
The UK National Institute for Health and Care Excellence has issued new guidelines on lipid lowering. The headlines are: lower the treatment threshold for primary prevention to people with a 10 year risk of 10%, use atorvastatin preferentially, and use the Qrisk assessment tool.1 This guidance, authored by a small group of important cholesterol ...
openaire +2 more sources
The UK National Institute for Health and Care Excellence has issued new guidelines on lipid lowering. The headlines are: lower the treatment threshold for primary prevention to people with a 10 year risk of 10%, use atorvastatin preferentially, and use the Qrisk assessment tool.1 This guidance, authored by a small group of important cholesterol ...
openaire +2 more sources